Keeley Asset Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Keeley Asset Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-500	Closed	-$23K	–	332
2015 Q3	$23K	Hold	500	–	–	﹤0.01%	322
2015 Q2	$16K	Buy	+500	New	+$14.5K	﹤0.01%	345

Other funds holding NAVB

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Keeley Asset Management's NAVB Position: Q4 2015 in Review

Keeley Asset Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2015, closing a stake of 500 shares — an estimated $23K sold.

Keeley Asset Management first reported a position in NAVB in Q2 2015 and held it in 2 quarters. The position peaked at $23K in Q3 2015. 78 funds tracked by Wall St. Rank hold NAVB as of Q4 2015.

Keeley Asset Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2015 after selling out during the quarter.
Keeley Asset Management sold 500 Navidea Biopharmaceuticals Inc. shares in Q4 2015, an estimated $23K.
Keeley Asset Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2015 and held it in 2 quarters.
Keeley Asset Management's Navidea Biopharmaceuticals Inc. position peaked at $23K in Q3 2015.
78 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2015.

Based on Keeley Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.